Advicenne Stock: price and insider trades · France

Advicenne is a French specialty pharmaceutical company focused on the development and commercialization of innovative treatments for rare kidney diseases. Listed on Euronext Growth Paris under the ticker ALDVI and ISIN FR0013296746, the company was founded in Nîmes in 2007 by Dr. Luc-André Granier and Caroline Roussel-Petit. Its business model is that of a niche rare-disease specialist, targeting severe conditions with high unmet medical need in both pediatric and adult patient populations. The company is now headquartered in Paris and operates with teams in France and the United States, reflecting its increasingly international scope.

Advicenne’s core asset is ADV7103, marketed in Europe under the brand name Sibnayal®. The product is a prolonged-release fixed-dose combination of potassium citrate and potassium bicarbonate designed to treat distal renal tubular acidosis (dRTA), a rare chronic kidney disorder. Sibnayal® received European marketing authorization in 2021, a major milestone that validated the clinical and regulatory strategy of the company. Advicenne is also developing the same asset in cystinuria, another rare renal disease, and has advanced regulatory and clinical work in both Europe and the United States. In November 2025, the group filed its U.S. registration application with the FDA for Sibnayal® in dRTA, underscoring its ambition to expand from a European commercial-stage niche player into a transatlantic rare-disease platform.